HK Stock Market Move |

MICROPORT (00853) rose by nearly 4%, trading at a 3.83% increase at the time of writing, closing at 5.97 Hong Kong dollars with a trading volume of 22.5752 million Hong Kong dollars. In recent news, MICROPORT issued an announcement stating that Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (688016.SH) expects to achieve operating income of 11.875 billion to 13.06 billion yuan in the fiscal year 2024, a year-on-year increase of 0.02% to 10.01%. The net profit attributable to the owners of the parent company in 2024 is expected to be between 4.925 billion and 5.41 billion yuan, representing a year-on-year increase of 0.01% to 9.86%. During the reporting period, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. continued to show growth with innovative products such as the Castor branch-type aortic membrane stent and delivery system, Minos abdominal aortic membrane stent and delivery system, and Reewarm PTX drug balloon dilation catheter. The new products Talos direct coronary aortic membrane stent system and Fontus branch-type intraoperative stent system have shown rapid growth in terms of hospital admissions and terminal implant volumes. However, considering the changing market environment in the second half of the year, factors such as adjustments to product prices and promotional strategies by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., have impacted the speed of sales growth and profits for the full year.